Screener
Sana Biotechnology SANA Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Contingent consideration, net of current portion | 80,907 | 83,518 |
| Success payment liabilities | 16,926 | 19,238 |
| Other non-current liabilities | 9,805 | 10,600 |
| Total liabilities | 254,353 | 256,006 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of March 31, 2026 and December 31, 2025 | - | - |
| Common stock, $0.0001 par value; 750,000 shares authorized; 269,817 and 266,732 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 27 | 27 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's total liabilities?
- Sana Biotechnology (SANA) reported total liabilities of $254.35M in Q1 2026.
- How has Sana Biotechnology's total liabilities changed year-over-year?
- Sana Biotechnology's total liabilities increased by 7.6% year-over-year, from $236.39M to $254.35M.
- What is the long-term trend for Sana Biotechnology's total liabilities?
- Over 5 years (2020 to 2025), Sana Biotechnology's total liabilities has grown at a -3.0% compound annual growth rate (CAGR), from $298.58M to $256.01M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Sana Biotechnology's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude